BOONE, N.C. – Early clinical studies have shown that a fully digital, soft mist inhaler developed by Pneuma Respiratory can effectively deliver a number of different types of medicines to the lungs. “More than 40 million people suffer from asthma or COPD in the U.S.,” said James Bauler, director of business development at Pneuma Respiratory. “It’s well documented that patients have problems adopting the correct inhaler technique and thus receiving the expected dose of medication both with dry powder and existing metered-dose inhalers. With a proven team of technology and health care leaders, Pneuma expects to make significant gains in pulmonary drug delivery.” The device uses electronic breath actuation and a soft mist ejector. As a patient inhales, the ejector senses the breath and activates automatically. This allows the medication droplets to ride into the lungs on the patients’ breath, without propellants. Paired with a mobile app, the device is capable of delivering real-time dose verification data. Two clinical studies with COPD patients using small-molecule asthma and COPD medications validated the platform using bronchodilation as the outcome. A feature of the device is its ability to deliver different sized droplets of medicine via its droplet ejector technology, which allows the device to potentially target different areas of the lungs, said Bauler.
LOUISVILLE, Ky. – Digital therapeutics company Revon Systems is partnering with Humana on a pilot for a select population of Medicare Advantage members diagnosed with chronic obstructive pulmonary disease. “We are pleased to work with Humana on their Bold Goal to reduce chronic disease by 20% by 2020,” said Ted Smith, CEO of Revon Systems, in a statement. “We know that COPD can be a challenge for patients to manage, and we hope that Revon’s Smart Symptom Tracker technology will result in more Healthy Days for the participating members.” The pilot will use Revon’s Smart Symptom Tracker mobile app and the free Breathe COPD Resource Kit, which contains a pulse oximeter and thermometer. The app features a self-triage function intended to guide members toward the right level of care. The program seeks to evaluate the impact of digital therapies on clinical and business outcomes.
‘mHealth is a huge opportunity for us to be as close to the patient as possible’
ATLANTA – Mobile telehealth and remote patient monitoring company SynsorMed is seeking strategic partnerships to reach patients with chronic obstructive pulmonary disease.
The company recently announced a partnership with oxygen delivery equipment manufacturer CAIRE Inc. that created “CAIREview powered by SynsorMed,” a mobile solution to monitor patient conditions outside of the hospital by connecting a patient’s oxygen concentrator to a customized dashboard and mobile app.
“We’re right there in that key space,” said Theo Harvey, co-founder of SynsorMed. “mHealth technology is a huge opportunity for us to be as close to the patient as possible.”
SynsorMed’s platform encourages patient engagement and compliance by combining telehealth, remote patient monitoring and machine learning. A mobile app connects to health monitoring devices in the home, collecting and analyzing data to give a complete picture of a patient’s health status.
SynsorMed is also seeking partnerships with health systems and clinicians, and is considering integrating a voice-enabled notification engine to its platform.
“In health care, it can seem like you’re going back in time when it comes to technology,” he said. “There was some initial hesitation by providers as telehealth solutions were just taking off, but we’re starting to see a shift as the newness is wearing off and mobile devices are becoming ubiquitous.”
MONTREAL – Tactio Health Group has teamed up with Medical International Research for a telehealth solution designed specifically to monitor COPD patients remotely. The solution adds Bluetooth-enabled MIR spirometers that integrate with TactioPM patient apps. “With MIR SmartOne, COPD patients being monitored remotely with TactioRPM systems can benefit from an easy and simple way to self-test, report and exchange with their pneumologist,” said Michel Nadeau, CEO of Tactio, in a statement. MIR SmartOne is a portable FEV1 and Peak Flow meter enabling simple personal self-tracking of lung health with clinical accuracy. Tactio RPM is an app-enabled platform that combines mobile apps, connected health integrations, patient questionnaires and digital coaching programs.
MADISON, Wis. –Propeller Health has extended its collaboration with respiratory medicine provider GSK.
The two companies began working together in 2015 to research and collect evidence from Propeller’s clip-on sensor and software platform used in conjunction with GSK’s ELLIPTA inhaler and respiratory medicines for asthma and COPD.
“We are excited to be working closely with GSK to make the sensor for the ELLIPTA inhaler available in our commercial programs, and for the first time, as part of commercial pilots with GSK outside the U.S.,” said David Van Sickle, CEO and co-founder of Propeller, in a statement.
The clip-on sensor for the ELLIPTA Inhaler automatically records medication use, which the Propeller platform analyzes and presents to patients and physicians through its data-driven digital interfaces, providing an in-depth view into adherence.
The Propeller sensor and software program for the ELLIPTA Inhaler received CE marking and clearance from the U.S. Food and Drug Administration last year.
“Digital innovations, like sensor technologies, will help us ensure patients receive the best possible package of care management and treatment for their respiratory condition,” said Eric Dube, senior vice president and head of GSK, in a statement.
AMSTERDAM – Royal Philips has launched a Trilogy family of portable ventilators for patients with COPD that connect to its cloud-based Care Orchestrator platform. “By connecting Trilogy to Care Orchestrator, we are further blurring the lines between hospital and home, and enabling interventions that could help to reduce hospitalizations and improve quality of care,” said Eli Diacopoulos, respiratory care business leader at Philips, in a statement. The medical-grade connectivity of the Trilogy ventilators is powered by Philips HealthSuite and Qualcomm Life’s 2net Platform. Philips and Qualcomm have had a partnership to advance connected health across the health continuum since 2016.
AMSTERDAM – Use of a Royal Philips noninvasive ventilation (NIV) device at home can save millions in readmission costs and reduced hospitalization rates for patients with severe chronic obstructive pulmonary disease (COPD), a recent study has found.
The Philips-sponsored study assessed whether a comprehensive strategy of care, including the use of the Philips Trilogy 100 NIV, can reduce the economic burden of managing patients with moderate to severe COPD.
“The study shows that there are actually significant economic advantages to continuing care at home for patients who require frequent hospitalizations for COPD exacerbations,” said Dr. Teofilo Lee-Chiong, chief medical liaison at Philips. “Hospital admissions and readmissions for worsening COPD account for a large portion of health care expenditure. The latter affects the patients, hospitals and payers alike.”
Conducted at Barnes Healthcare Services, the study’s at-home program of care included advanced NIV therapy with the Trilogy, oxygen therapy, respiratory therapist-led care, patient education and medication reconciliation. It found that the reduction in readmissions led to a cumulative hospital savings of more than $400,000 over 30 days. After examining 1,000 COPD patients being treated with the combined treatment method, hospitals saved $1.6 million in the first 30 days, compared to no NIV treatment or less advanced NIV therapy devices. Payers had a cumulative 3-year savings of $326 million when using home NIV in comparison to no NIV treatment.
Lee-Chiong said NIV assists patients with breathing by providing a prescribed volume of air during inspiration. Newer technologies, like the Philips Trilogy, continuously adjust the delivered pressure to reach clinically desired targets and synchronize with the patient’s patterns of breathing.
The NIV model used in the study can be easily adopted by other health care providers, facilities and payers, said Lee-Chiong.
“As health systems continue to promote value-based care, it is increasingly important to demonstrate that programs like these can reduce costs while improving patient experiences,” he said.
ONTARIO, Canada – People with COPD could be persuaded to increase their levels of physical activity through a mobile app, a study in the Journal of Medical Internet Research has found.
“The findings suggest a system that supports dialogue between the user and the technology, alongside supporting the primary task to promote self-regulation of physical activity, is likely to be acceptable to people with COPD and perceived as persuasive,” said the study’s authors in an article published in the JMIR.
The study examined three prototypes for mobile apps using different persuasive technology design principles: dialogue support, primary task support and social support. Opinions of the prototypes were gathered from people with COPD, caregivers and health care professionals, and participants also ranked how likely techniques would be to convince them to use a technology designed to support physical activity.
The prototypes for mobile apps were positively received by participants and the prototype using a dialogue support approach was identified as the most likely to be used or recommended.
“Dialogue support and primary task support approaches are considered to be both acceptable and likely to be persuasive by people with COPD, caregivers and health care professionals,” the researchers said. “In the future, these approaches should be considered when designing apps to encourage physical activity by people with COPD.”
MINNEAPOLIS – Connected health solutions provider HealthFactors and Koronis Biomedical Technologies have announced a collaboration to improve health care and outcomes for people with respiratory conditions associated with asthma, COPD and cystic fibrosis. The companies will work on developing products and initiatives including algorithms that are used in smart inhalers. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health providers, families and caregivers,” said Patrick Lichter, co-founder, president and chief technology officer of KBT, in a statement. “This type of digital solution surrounds the patient and creates a truly connected experience that factors in all aspects of their lives and health care journey.” Throughout the collaboration, HealthFactors and KBT will partner with device manufacturers, pharmaceutical companies, researchers and clinicians who are focused on emerging treatments and therapies for respiratory and other complex medical conditions.
MINNEAPOLIS, Minn. – HealthFactors and Koronis Biomedical Technologies will work together on a variety of products and initiatives to improve health care and outcomes for people living with respiratory conditions associated with asthma, COPD and cystic fibrosis. “Our collaboration with KBT blends decades of expertise in technology, engineering, research, health care delivery and pharmaceuticals to deliver patient-centered solutions,” said Dan Spors, chief commercial officer of HealthFactors, in a statement. The collaboration will include the development of algorithms that are used in smart inhalers, and several clinical and technology advancements needed for the implementation of these inhalers into mainstream clinical practice. “Breakthrough treatments for complex medical conditions are being driven by a marriage of leading-edge electronic and software technology and advanced algorithms that deliver information from devices to patients, health care providers, families and caregivers,” said Patrick Lichter, president, co-founder and chief technology officer at KBT, in a statement.